MORNING NEWS

Market strategy by Swissquote Analysts

Intel Shares Plunge More Than 20% on Weak PC-Market Outlook

Oct 30, 2026
Intel INTC shares plunged more than 20% in after-hours trading on Thursday after the company reported disappointing third-quarter results and forecasted a prolonged slowdown in personal-computer sales. Much of the pressure on the PC segment is coming from the persistently high price of memory chips, and the company expects that pressure to remain in 2028.

Samsung Electronics Under Pressure Despite Record Profits

Oct 29, 2026
Samsung Electronics reported its fourth consecutive quarter of record earnings as its core semiconductor business continued to ride the AI-driven demand wave, though the results fell short of lofty expectations amid growing calls for higher shareholder returns.

SK Hynix Plans $75 Billion in Shareholder Returns After Blockbuster Results

Oct 28, 2026
South Korean memory chip giant SK Hynix plans to distribute a total of $75 billion to its shareholders this year. The company is benefiting massively from booming demand for hardware used in artificial intelligence (AI) applications. The world’s second-largest memory chip manufacturer reported another blockbuster set of results on Wednesday.

HSBC Quarterly Profit Climbs, Plans $1 Billion Buyback

Oct 27, 2026
HSBC Holdings reported higher third-quarter net profit and announced a new share buyback of up to $1 billion. The London-based bank said Tuesday that net profit rose 45% from a year earlier to $7.09 billion for the three months ended Sept. 30. That still missed the estimate of $7.24 billion in a poll of analysts by data provider Visible Alpha.

Roche Targets Emerging Oncology Market with New Lung Cancer Drug

Oct 26, 2026
Roche aims to make a pill developed by the Swiss pharmaceutical company a standard treatment for an advanced form of lung cancer. It marks the company’s first foray into an emerging field within the oncology market. Roche is working on several drugs that target a cancer driver that has long eluded the industry. A breakthrough in pancreatic cancer by the U.S. biotech company Revolution Medicines brought the field to investors’ attention, and Roche aims to enter this space with the lung cancer drug Divarasib.

Holcim Reports Higher Revenue and Operating Profit in the Third Quarter

Oct 23, 2026
At Holcim, revenue and operating profit grew significantly in the summer quarter. Overall, revenue increased by 15.5 percent to 4.66 billion Swiss francs from July through the end of September 2026, as Holcim announced on Friday. For the first time in a long while, the compa

Nestlé Reports Higher Quarterly Sales

Oct 22, 2026
Nestlé gained momentum in the third quarter of 2026. The world’s largest food company posted organic growth of 4.0 percent, up from 3.7 percent in the previous quarter. So-called real internal growth (RIG) reached 2.8 percent, as Nestlé announced on Thursday.

SpaceX Reports First Profit as a Publicly Traded Company

Oct 21, 2026
SpaceX SPCX and Tesla TSLA have formed special committees to discuss a potential merger, Elon Musk said Tuesday. Musk’s comments came toward the end of SpaceX’s quarterly earnings call in which executives said revenue more than doubled from a year earlier, and signaled more robust growth in the months ahead.

ABB Reports a Significant Increase in Orders in the Third Quarter

Oct 20, 2026
ABB continued to grow operationally in the third quarter of 2026. As in the first two quarters, revenue and order intake posted double-digit growth, with the latter performing exceptionally well, thanks in no small part to data centers.

Lindt & Sprüngli announces leadership changes

Oct 19, 2026
Lindt & Sprüngli announced on Monday that Group CEO Adalbert Lechner will leave the company. The Board of Directors has initiated a search process to identify his successor.
Switzerland

Designed with passion in Switzerland

General Information

This website is operated jointly by Swissquote MEA Ltd. ("SQMEA") and Swissquote Bank SA’s Representative Office in Dubai (the "Swissquote Representative Office"). SQMEA is incorporated in the Dubai International Financial Centre ("DIFC") and regulated by the Dubai Financial Services Authority ("DFSA"). The Swissquote Representative Office is licensed by the Central Bank of the United Arab Emirates to carry out representative office activities only. Swissquote Bank SA ("SQB") is incorporated in Switzerland and regulated by the Swiss Financial Market Supervisory Authority (FINMA).

Depending on the section of the website, content may be communicated by Swissquote MEA Ltd ("SQMEA") or by Swissquote Bank SA’s UAE Representative Office (the "Swissquote Representative Office").

SQMEA does not participate in and nor is it associated with Financial Promotion through parts of the website which refer to contracts for differences (CFDs), leveraged rolling spot forex contracts, or other Restricted Speculative Investments, as defined in the DFSA Rulebook. SQMEA does not deal as agent, arrange, advise on or refer Clients to any person in relation to such Restricted Speculative Investments.

Content on the website relating to Restricted Speculative Investments is communicated exclusively by the Swissquote Representative Office in its representative and marketing capacity. The Swissquote Representative Office does not itself provide the relevant financial products or services. Such products and services are provided by Swissquote Bank SA ("SQB"), Switzerland.

SQMEA does not make or approve any Financial Promotion on the website in relation to Crypto Business and does not refer Clients to SQB in relation to Crypto Business services. Content in these sections relating to Crypto Business and the relevant products and services are provided by SQB. For users of those parts of the website which refer to Restricted Speculative Investments and Crypto Business, the products and services presented in these sections are provided by SQB and not by SQMEA.
 
No Offer or Advice
The content of this website is provided for information purposes only and does not constitute investment advice, a recommendation, a solicitation, or an offer to buy or sell any financial instruments.
Nothing on this website should be relied upon as the sole basis for making investment decisions. Visitors should seek independent financial, legal, and tax advice before making any investment.
 
Product Availability and Eligibility
Access to products and services described on this website is subject to applicable laws, regulations, and eligibility requirements.
Certain products or services may not be available in all jurisdictions or to all clients, and additional conditions or restrictions may apply.
 
Risk Warning
Investing in financial instruments involves risk, including the possible loss of capital. Past performance is not a reliable indicator of future results.
Further information is available in the "Risks Involved in Trading Financial Instruments" disclosure.

AI-Generated Content

Some visual or editorial content on this website may be generated or enhanced using artificial intelligence (AI) tools.
All such content is subject to human review and approval to ensure accuracy, appropriateness, and compliance with applicable regulatory requirements. AI is not used to provide personalised investment advice, suitability assessments, or client-specific recommendations.